iQure Pharma

iQure Pharma is a clinical-stage biotechnology company developing first-in-class astrocyte-targeted therapeutics for CNS disorders. The company's approach focuses on restoring glutamate homeostasis to break the cycle of excitotoxicity, targeting conditions where glutamate imbalance drives neurological damage.